Trastuzumab Injection | MedPath Search

Found 10 clinical trials|View Analysis

Sort by:

Need a comprehensive medical report on "Trastuzumab Injection"?

Analyze the latest clinical research and treatment options

Summarize scientific findings from medical journals

Pyrotinib Combined With Trastuzumab Subcutaneously Compared Intravenous Administration in the Treatment of HER2-positive Early Breast Cancer

Not yet recruiting

Conditions: HER2+ Breast Cancer

Interventions: Drug: Trastuzumab intravenous drip/Trastuzumab Subcutaneous Injection

First Posted Date: 2024-08-05

Last Posted Date: 2024-08-05

Lead Sponsor: Jiangsu Famous Medical Technology Co., Ltd.

Target Recruit Count: 100

Registration Number: NCT06537674

A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer

Phase 3

Recruiting

Conditions: HER2-PositiveRecurrent or Metastatic Breast Cancer

Interventions: Drug: Trastuzumab Injection；Pertuzumab Injection ； Docetaxel Injection
Drug: SHR-A1811 Injection ； Pertuzumab Injection
Drug: SHR-A1811 Injection

First Posted Date: 2023-09-28

Last Posted Date: 2025-04-20

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 864

Registration Number: NCT06057610

Locations: 🇨🇳
The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China

Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer.

Phase 3

Active, not recruiting

Conditions: HER2-positive Breast Cancer

Interventions: Drug: Perjeta + Trastuzumab + Docetaxel
Drug: TQB2440 injection + Trastuzumab + Docetaxel

First Posted Date: 2023-08-14

Last Posted Date: 2023-08-14

Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Target Recruit Count: 412

Registration Number: NCT05985187

Locations: 🇨🇳
The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China
🇨🇳
Sun Yat-sen University Cancer Prevention Center, Guangzhou, Guangdong, China
🇨🇳
Affiliated cancer hospital of harbin medical university, Harbin, Heilongjiang, China

and more 3 locations

A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer

Phase 2

Recruiting

Conditions: Gastric Cancer

Interventions: Drug: RC48-ADC
Drug: Toripalimab
Drug: Trastuzumab Injection
Drug: Oxaliplatin injection
Drug: Capecitabine

First Posted Date: 2023-08-08

Last Posted Date: 2024-06-24

Lead Sponsor: RemeGen Co., Ltd.

Target Recruit Count: 130

Registration Number: NCT05980481

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, China

Clinical Study to Compare the Pharmacokinetics and Safety of Trastuzumab for Injection With Herceptin® in Healthy Male Volunteers

Phase 1

Completed

Conditions: Metastatic Breast Cancer
Metastatic Gastric Cancer

Interventions: Drug: Herceptin
Drug: Trastuzumab for injection

First Posted Date: 2023-03-13

Last Posted Date: 2023-03-13

Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Target Recruit Count: 89

Registration Number: NCT05765357

Locations: 🇨🇳
Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Changchun, Jilin, China

Phase II Clinical Study of T-DM1 and Pyrotinib Maleate in Patients With HER2-positive Metastatic Breast Cancer Who Had Progressed on TKI Therapy

Not Applicable

Not yet recruiting

Conditions: HER2+ Advanced Breast Cancer Patients Progressing on TKI Therapy

Interventions: Drug: Trastuzumab Emtansine for Injection
Drug: Pyrotinib Maleate Tablets

First Posted Date: 2022-09-29

Last Posted Date: 2022-10-03

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 50

Registration Number: NCT05560308

A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer

Phase 2

Recruiting

Conditions: Metastatic Breast Cancer
Advanced Breast Cancer

Interventions: Drug: MRG002
Drug: Trastuzumab Emtansine for Injection

First Posted Date: 2021-06-14

Last Posted Date: 2023-03-17

Lead Sponsor: Shanghai Miracogen Inc.

Target Recruit Count: 350

Registration Number: NCT04924699

Locations: 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳
Fifth Medical Center of PLA General Hospital, Beijing, Beijing, China
🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

and more 16 locations

Clinical Trial of Comparative Study of GB221 Pharmacokinetics

Phase 1

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Coprelotamab Injection
Drug: Trastuzumab Injection

First Posted Date: 2019-11-22

Last Posted Date: 2019-12-18

Lead Sponsor: Genor Biopharma Co., Ltd.

Target Recruit Count: 32

Registration Number: NCT04175171

Locations: 🇦🇺
Linear Clinical Research Limited, Nedlands, Western Australia, Australia

Phase III to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Trastuzumab Injectable Solution
Drug: Trastuzumab Injectable Product
Drug: Trastuzumab Injection

First Posted Date: 2013-06-11

Last Posted Date: 2023-04-05

Lead Sponsor: Spanish Breast Cancer Research Group

Target Recruit Count: 166

Registration Number: NCT01875367

Locations: 🇪🇸
Hospital de Mataró, Mataró, Barcelona, Spain
🇪🇸
Hospital de Manacor, Manacor, Illes Balears, Spain
🇪🇸
Hospital General Universitario de Granollers, Granollers, Barcelona, Spain

and more 24 locations

Clinical Value of 89Zr-trastuzumab PET

Phase 2

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: 89Zr-trastuzumab injection

First Posted Date: 2013-04-15

Last Posted Date: 2015-11-05

Lead Sponsor: University Medical Center Groningen

Target Recruit Count: 20

Registration Number: NCT01832051

Locations: 🇳🇱
University Medical Center, Groningen, Netherlands